Whole Network Most Recent TOP10 Gene Therapy Microbiology Nanomedicine Stem Cells

« Ribomed Biotech Granted... | Main | Chelsea Therapeutics... »

Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Patents and Intellectual Property Rights by ruth on February 14, 2006

In a revised, expanded agreement, Amgen receives exclusive worldwide rights to develop and commercialize Biovitrum's drug candidate for Type 2 diabetes and related metabolic Diseases links

. Previously, Amgen had exclusive rights to commercialize products only in North and South America, the European Union, Australia and New Zealand.

Biovitrum's lead compound, 11beta-HSD1 enzyme inhibitors, are currently under early clinical development.

Permalink: Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes
Tags: diabetes amgen biotech type rights type+diabetes biovitrum+lead candidate+type

Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/15480

Related Entries:

Amgen Acquires Abgenix for $2.2 B - 15 December 2005

Top 20 Molecular Millionaires - 31 May 2006

entry_title - 00 December 0000

Obesity Leads to Type 2 Diabetes - 05 February 2007

Amgen Buys Ilypsa for $420 Million - 06 June 2007

Novo Nordisk's Levemir®, Approved in Japan - 23 October 2007

'Laziness' of Regulatory T-cells, Lead to Type 1 Diabetes - 18 January 2008

Diet and Type 2 Diabetes - 15 July 2008

Vote for Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:

Currently 6.00/10
1
2
3
4
5
6
7
8
9
10

Rating: 6.0 out of 1 vote(s) cast.

Add your response to Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes: Response from: James Hatton So when they expanded the collaboration, I wonder what the "rest of the world" was worth? When they signed the 2003 license (the winner of the "Best of Biotech 2004" award for "Most Creative and Significant Deal"), the September 8, 2003 press release disclosed that the license fee was $87 million.
Name: *	Email: (will never be shown)*	URL:

(* marked fields are required)
Notify me if more comments appear?	Subscribe to The Biotech Weblog newsletter? (Newsletters are sent out weekly).	Remember me
Security Code: * (Please help us to sort out spam.)

Please enter your comment here: (Sorry, no HTML is allowed - URLs will be made clickable automatically if you add http:// to your URL.)


We welcome your comments, however all comments are moderated. Offensive or off-topic comments will be deleted and not displayed.

RSS	\| See all blog subscribe options
Google	\| What is RSS?
Yahoo!
Addthis
Bloglines
Newsletter

Check out our Sponsored Blogs!
The Mobile Technology Weblog

Contributors (Last 90 days)
Gloria Gamat (3)
Ruth Schaffer (33)
This site has 1195 entries and is powered by Creative Weblogging since July 2005.
Do you want to start or edit an existing blog for us and get paid? More info.
Do you want to advertise on this blog? We have great ideas!
Do you have tips for us? Send them!

Advertise with us
Learn more about our advertising options or email advertising - at - creative-weblogging.com or give Luis a call at +1 (650) 331 8047.

Testimonials
'Very nice blog layout with great content. Are you interested in Star Trek props that are quickly becoming reality? Then this is the blog for you. Human medical scanners, nano technology and more great technological advancements.' -VirtualLoop Blog of the Week

'I subscribe to your blog and have been enjoying your posts and perspective.'

Other blogs in the same channel in the Creative Weblogging Network

Disclaimer
Some of the contents of this site are protected Creative Weblogging Ltd. 2004-2008.

Tell a friend about Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes
Recipient email:*	Your email:*

(* Both email addresses are required for sending this article. They will never be shown or used for any marketing purposes)
Please enter a message which will be shown together with the article:

Security Code: (Please help us to sort out spam.)

Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Patents and Intellectual Property Rights by ruth on February 14, 2006

Related Entries:

Vote for Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:

Add your response to Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:

Tell a friend about Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes

Check out our Sponsored Blogs!

Our Editors recommend

Contributors (Last 90 days)

Categories

Archives

Advertise with us

Most popular

Testimonials

Recent Comments

Other blogs in the same channel in the Creative Weblogging Network

Life Sciences

Disclaimer

Find more recent entries from our other publications:

Allergies

Straightfromthedoc

Daily Diabetic

Hidden Travel Gems

The Outsourcing Weblog

Networking for Pros